BUZZ-Bluebird down after Q3 revenue misses estimates, BofA cuts rating

Reuters11-16

** Shares of gene therapy developer bluebird bio Inc

fall ~10% to record low of 32 cents

** On Thursday, co posted Q3 sales of $10.6 mln, missing analysts est of $18.1 mln - LSEG data

** BofA Global Research downgrades BLUE to "neutral" from "buy" and cuts its estimate for peak revenue of Lyfgenia, co's gene therapy for sickle cell disease, to $540 mln from $730 mln

** Brokerage also cuts its estimate for co's 2025 revenue to $150 mln from ~$190 mln

** Lyfgenia received FDA approval in Dec last year, making it the biggest product for BLUE so far due to large patient population

** Two of 11 brokerages rate the stock "buy" or higher, 6 "hold" and 3 "sell; their median PT is $1.51 - LSEG data

** BLUE stock down ~76% YTD, including session gains

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment